

LA JOLLA PHARMACEUTICAL CO
Form 8-K
March 20, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 20, 2017

LA JOLLA PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)

California (State or other jurisdiction	1-36282 (Commission	33-0361285 (I.R.S. Employer
of incorporation or organization)	File Number)	Identification No.)
10182 Telesis Court, 6th Floor, San Diego, California 92121		

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (858) 207-4264

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS.

On March 20, 2017, La Jolla Pharmaceutical Company issued a press release announcing a proposed offering of its common stock. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit

No.	Description
23.1	Consent of Independent Registered Public Accounting Firm Squar Milner LLP
99.1	Press Release Announcing Proposed Offering of Common Stock (March 20, 2017) * * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: March 20, 2017

By: /s/ George F. Tidmarsh
Name: George F. Tidmarsh, M.D., Ph.D.
Title: President and Chief Executive Officer

EXHIBIT INDEX

Exhibit

No.	Description
23.1	Consent of Independent Registered Public Accounting Firm Squar Milner LLP
99.1	Press Release Announcing Proposed Offering of Common Stock (March 20, 2017)